Recruiting

PMEGs

Sponsor:

Beth Israel Deaconess Medical Center

Code:

NCT04746677

Conditions

Abdominal Aortic Aneurysm

Thoracoabdominal Aortic Aneurysm

Aortic Dissection

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Endovascular aortic repair with a physician-modified endovascular graft (PMEG)

TREO graft

Study Details

Brief summary:

The primary objective of this study is to examine the safety and effectiveness of physician-modified endovascular grafts (PMEGs) for endovascular repair of complex aortic pathology in high-risk patients. The study is divided into three study arms based on the subject's aortic pathology: (1) Complex abdominal aortic aneurysm (AAA); (2) Thoracoabdominal aortic aneurysm; and (3) Aortic dissection.

Conditions

Abdominal Aortic Aneurysm

Thoracoabdominal Aortic Aneurysm

Aortic Dissection

Study ID

NCT04746677

Start date

Mar 15, 2021

Status verified date

Apr, 2026

Completion date

Mar 31, 2031

Anticipated

Primary completion date

Mar 31, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

INCLUSION CRITERIA:

General inclusion criteria (applicable to all 3 study arms):

  • Aortic pathology that fits one of the study arms (see below for detailed description)
  • Aortic pathology that cannot be treated within the Instructions for Use of an FDA- approved, commercially-available device
  • Aortic aneurysm that can be treated within the Instructions for Use of an FDA-approved, commercially-available custom-manufactured device but deemed unsafe to wait the required time for device manufacturing
  • Subject is at high-risk of morbidity and mortality with open surgical repair based on cardiopulmonary function, extent of comorbid disease, and anatomic complexity
  • Iliac and/or femoral access vessel morphology that is compatible with vascular access techniques, devices, or accessories, with or without use of a surgical or endovascular conduit
  • Non-aneurysmal aortic segment proximal to the aortic pathology with a:

  • Minimum neck length of 20 mm
  • Diameter between 20 - 42 mm
  • Non-aneurysmal aortic or iliac segment distal to the aortic pathology with:

  • Aortic distal fixation site greater than 20 mm in length and diameter between 20-42 mm
  • Iliac artery distal fixation site greater than 10 mm in length and diameter range 8- 25 mm
  • Age ≥21 years old
  • Life expectancy: ≥2 years

Arm1:

  • Complex abdominal aortic aneurysm, specifically juxtarenal or suprarenal abdominal aortic aneurysm or type IV thoracoabdominal aortic aneurysm, with maximum diameter of ≥5.5 cm for men or ≥5.0 cm for women, growth ≥0.5 cm in 6 months, or concomitant iliac aneurysm ≥3 cm
  • Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair, without aneurysmal disease extending above the diaphragmatic hiatus
  • Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and/or CA for repair, without aneurysmal disease above the diaphragmatic hiatus
  • Saccular complex abdominal aortic aneurysm deemed at significant risk for rupture
  • Symptomatic complex aortic aneurysm
  • Penetrating aortic ulcer with depth ≥1 cm or width ≥2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, without involvement of the aorta above the diaphragmatic hiatus
  • Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, without involvement of the aorta above the diaphragmatic hiatus

Arm2:

  • Type I, II, or III thoracoabdominal aortic aneurysm with maximum diameter of ≥5.5 cm, or growth ≥0.5 cm in 6 months
  • Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair with aneurysmal disease extending above the diaphragmatic hiatus
  • Prior thoracic endovascular aneurysm repair with loss of distal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair
  • Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and/or CA for repair, with aneurysmal disease above the diaphragmatic hiatus
  • Saccular type I, II, or III thoracoabdominal aortic aneurysm deemed at significant risk for rupture
  • Symptomatic type I, II, or III thoracoabdominal aortic aneurysm
  • Penetrating aortic ulcer with depth ≥1 cm or width ≥2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, with involvement of the aorta above the diaphragmatic hiatus
  • Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, with involvement of the aorta above the diaphragmatic hiatus

Arm 3:

  • Acute or chronic type B aortic dissection with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or persistence of symptoms despite optimal medical therapy
  • Prior repair of type A dissection and development of acute or chronic type B dissection component with indication for repair (listed above)
  • Aortic intramural hematoma (IMH) with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or more typically, persistence of symptoms despite optimal medical therapy

Arm 4

  • Patient does not meet the inclusion/exclusion criteria of Arms 1 - 3
  • Patient has prohibitive operative risk for open repair and no other viable endovascular treatment option
  • Estimated perioperative risk is lower than the estimated 1-year mortality without surgery

EXCLUSION CRITERIA:

General Exclusion Criteria

  • Subject is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site
  • Subject is unwilling to comply with the follow-up schedule
  • Inability or refusal to give informed consent by subject or legal representative
  • Subject is pregnant or breastfeeding
  • Subject has a ruptured aneurysm

Arm 5 • Patient meets criteria for Arms 1-4

\- Patient is undergoing repair using the TREO bifurcated stent graft

Indications for using TREO bifurcated stent graft:

  • Patient has undergone a prior endovascular aortic repair and meets criteria for repair; OR
  • -Patient has measured length from the lowest renal artery to the aortic bifurcation (either de novo or from a prior endograft) < 115 mm; OR

  • In patients with notable vessel tortuosity, where centerline measurement may not accurately reflect the distance covered needed in situ; OR
  • Additional clinical or anatomic scenarios where forthcoming experience may demonstrate the TREO endograft to be superior to the currently-used Alpha/Alpha 2 endograft.

Medical Exclusion Criteria

  • Known sensitivities or allergies to the materials of construction of the devices
  • Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
  • Uncorrectable coagulopathy
  • Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment
  • Systemic or local infection that may increase the risk of endovascular graft infection
  • Diagnosis of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome)

Anatomic Exclusion Criteria

  • Inability to perform open or endovascular iliac conduit in patients with inadequate femoral/iliac access
  • Excessive thrombus or calcification within the neck of the aneurysm
  • Visceral vessel anatomy not compatible with placement of a physician-modified endovascular graft due to occlusive disease or small size

Study Design

Enrollment

220 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Complex abdominal aortic aneurysm (AAA)

Includes juxtarenal AAA, suprarenal AAA, and type IV thoracoabdominal aortic aneurysm

experimental: Thoracoabdominal aortic aneurysm (TAAA)

Includes Type I, Type II, and Type III TAAA

experimental: Type B aortic dissection

Includes all Type B dissections

experimental: Expanded Selection Arm

Includes high risk subjects who do not meet inclusion criteria for Arms 1-3

experimental: Expanded Treatment

Includes subjects who will have the PMEG TREO graft

Interventions

Endovascular aortic repair with a physician-modified endovascular graft (PMEG)

Endovascular aortic repair with a physician-modified endovascular graft (PMEG)

TREO graft

Endovascular aortic repair with a physician-modified endovascular graft (PMEG) using the TREO graft

Primary outcome measure

  • Perioperative mortality [ Time Frame: Up to 30-days after surgery ]
  • Perioperative major adverse events [ Time Frame: Up to 30-days after surgery ]
  • All-cause mortality [ Time Frame: 30-days to 5-years ]
  • Aneurysm-related mortality [ Time Frame: 30-days to 5-years ]
  • Long-term major adverse events [ Time Frame: 6-months to 5-years ]
  • Technical success [ Time Frame: 24 hours ]
  • Device-related reintervention [ Time Frame: 30-days to 5-years ]
  • Aneurysm rupture [ Time Frame: 30-days to 5-years ]
  • Conversion to open repair [ Time Frame: 30-days to 5-years ]
  • Endoleaks [ Time Frame: 30-days to 5-years ]
  • Main device occlusion [ Time Frame: 30-days to 5-years ]
  • Target vessel patency [ Time Frame: 30-days to 5-years ]
  • Residual aneurysm sac status [ Time Frame: 6-months, 1-year, and annually to 5-years ]

Central Contacts and Locations

Central contacts

Jessica Kelliher, BSN

617-632-7845jjkellih@bilh.org

Locations

Beth Israel Deaconess Medical Center

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Jessica Kelliher, BSN

617-632-9975jjkellih@bilh.org

Principal Investigator:

Marc L Schermerhorn, MD

More Information

Sponsor

Beth Israel Deaconess Medical Center

Last update posted

Apr 8, 2026

Last verified

Apr, 2026

Keywords

  • Fenestrated endovascular aortic repair
  • Branched endovascular aortic repair
  • Complex aortic aneurysm repair

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Beth Israel Deaconess Medical Center on 2026-04-08.